Harbor Multi asset Explo... Aktie - MAPP

Professionelle Tools für Privatanleger.

Premium

Current Price

22,9523

Gebot

Fragen

Volumen

23,02 Tagesbereich 23,02

21,118 52-Wochen-Bereich 24,19

Handelsende

23,2178

Handelsbeginn

23,02

Letzte Trade

100

22.9523

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

117

Finanzvolumen

VWAP

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.2305	-0.994271615163	23.1828	23.44	22.9523	23	23.34393362	SP
4	-0.5077	-2.16410912191	23.46	23.71	22.7074	69	23.23370072	SP
12	0.0123	0.0536181342633	22.94	24.13	22.5451	117	23.47685465	SP
26	-0.5377	-2.28905917412	23.49	24.19	22.5451	123	23.6097548	SP
52	1.1786	5.41295232322	21.7737	24.19	21.118	212	22.82769879	SP
156	2.8123	13.9637537239	20.14	24.19	18.9015	584	20.81144048	SP
260	2.8123	13.9637537239	20.14	24.19	18.9015	584	20.81144048	SP

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
LX31Lexicon Pharmaceuticals Inc	0,5745 € (79,98%)	329,4k
AMIMedondo Holding AG	0,45 € (73,08%)	3,1k
CK1RAREX LTD	0,018 € (50,00%)	32,7k
DBVDBV Technologies	1,114 € (42,82%)	108,08k
OL11Euro Sun Mining Inc	0,0678 € (34,52%)	191,06k
MDG1Medigene AG	0,75 € (-51,52%)	40,73k
CR6AWolfspeed Inc	2,50 € (-50,10%)	969,3k
VOPInvestigator Resources Ltd	0,0115 € (-34,29%)	3,94k
EJ7Energy Resources of Australia	0,001 € (-33,33%)	86,2k
E7TAlexium International Group Share	0,0045 € (-30,77%)	34,05k
FMKEcograf Limited	0,1565 € (-13,77%)	9,14M
PF8European Lithium Limited	0,022 € (-8,33%)	5,3M
D7GNel ASA	0,2149 € (-5,16%)	4,26M
3CPXiaomi Corporation	5,871 € (-4,46%)	3,03M
DMJDynaCERT Inc	0,113 € (-6,61%)	2,02M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Harbor Multi asset Explorer ETF (MAPP)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

MAPP Neueste Nachrichten

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Harbor Multi asset Explorer ETF (MAPP) Börsenkurse

Harbor Multi asset Explorer ETF (MAPP)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

MAPP Neueste Nachrichten

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen